Progenics Pharmaceuticals Inc
Opko Health: Q2 Expenditures, Developments, Recommendations
Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.
How Analysts View Amicus Therapeutics in September
Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Why Invitae Stock Rose 23% in Week Ended August 24
On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99.
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
How Opko Health Fared in the Second Quarter of 2018
Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.
What Analysts Think of PolarityTE and Its Peers
In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.
What’s the Upside Potential of Nektar Therapeutics?
Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.